CAR T-cell therapy allows us to engineer your own cells to fight your cancer from within. Our program was one of the first to be certified in CAR T-cell therapy for adults with recurrent or persistent diffuse large B-cell lymphoma (DLBCL), a common type of non-Hodgkin lymphoma, and children and young adults (at NewYork-Presbyterian Morgan Stanley Children’s Hospital) with recurrent or persistent acute lymphoblastic leukemia (ALL).
Our team’s expertise and skill, along with access to top specialists from all areas of medicine in one medical center, make the HICCC the place to receive this potentially lifesaving treatment.
What is CAR T-cell therapy?
CAR T-cell therapy is a type of immunotherapy that trains the immune system to attack cancer with a patient’s own T-cells, a type of white blood cell. CAR stands for "chimeric antigen receptor." In CAR T-cell therapy, our specialized teams collect T cells from the patient and engineer them to express the CAR, turning these cells into ‘serial killers’ that seek and destroy cancer cells.
CAR-T cell therapy is a powerful new tool for clinicians and researchers at the HICCC in the fight against cancer.